Un nou examen de sânge poate identifica 12 tipuri de cancer înainte de manifestarea simptomelor.

A recent breakthrough in cancer detection has emerged through the development of a blood test called miONCO-Dx, created in the UK by Xgenera in collaboration with the University of Southampton. This innovative test is capable of identifying early signs of 12 different types of cancer, even before symptoms manifest, marking a significant advancement in early cancer diagnosis.

The miONCO-Dx test is designed to analyze just 10 drops of blood, searching for microRNAs (miRNAs). These small molecules play a critical role in the regulation of genes, and any abnormality in their levels can indicate the presence of cancer cells. Utilizing artificial intelligence, the test can accurately interpret the results and pinpoint the tumor’s location within the body.

The 12 types of cancer that miONCO-Dx can detect include:

– Lung cancer
– Gastric cancer
– Prostate cancer
– Esophageal cancer
– Liver cancer
– Bladder cancer
– Ovarian cancer
– Intestinal cancer
– Pancreatic cancer
– Breast cancer
– Bone sarcoma and soft tissue tumors
– Glioblastoma (a type of brain tumor)

Impressive results have been obtained from screenings conducted on approximately 20,000 individuals, revealing a remarkable accuracy rate of 99% in cancer detection and precise tumor localization. Early diagnosis of cancer significantly increases the chances of successful treatment, underscoring the importance of such innovations in medical diagnostics.

The next phase for the miONCO-Dx test involves a validation and verification study in partnership with the British Department of Health, which will include around 8,000 participants. This evaluation will assess the test’s readiness for potential integration into the National Health Service (NHS), paving the way for broader access to early cancer detection methods.

The potential impact of miONCO-Dx on public health is substantial, as it could revolutionize how cancers are diagnosed, leading to timely interventions and improved outcomes for patients. By catching cancer at earlier stages, the test aims to enhance survival rates and decrease the long-term burden on healthcare systems.

In summary, miONCO-Dx represents a significant advancement in cancer detection technology, leveraging the precision of blood analysis and artificial intelligence to potentially save lives through early intervention. Its ongoing validation will determine its future role in routine health screenings and cancer management strategies.